1. MARKETS
  2. SECTOR : DIVERSIFIED CONSUMER SERVICES
  3. INDUSTRY : HEALTHCARE SERVICES
  4. NEOGENOMICS INC.

Neogenomics Inc. XNAS: NEO

Neogenomics Inc. Live Share Price Today, Share Analysis and Chart

Weak Stock
Download real time

9.48 0.07 (0.74%)

50.42% Fall from 52W High

1.8M XNAS Volume

XNAS 27 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Neogenomics Inc. Key Metrics

Select

Market Capitalization

Below industry Median
1,217.8

PE TTM

Negative PE TTM
-15.5

PEG TTM

Negative PEG TTM
-1.5

Price to Book

Below industry Median
1.3

Institutional holding current Qtr %

High in industry
96.9

Revenue Growth Qtr YoY %

Below industry Median
10.6

Operating Revenue growth TTM %

Below industry Median
11.6

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-7

Net Profit TTM Growth %

Below industry Median
10.5

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-9.7

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-12.9

Piotroski Score

Below industry Median
4

Rel Perf vs Sector quarter%

-42.5

ROE Annual %

Negative ROE Annual %
-8.5

RoA Annual %

Negative RoA Annual %
-4.7
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Low Financial Strength
27.8 / 100
Valuation Score
Expensive Valuation
15.3 / 100
Momentum Score
Technically Bearish
31.6 / 100
Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM
Analyst Price Target
19
1Yr Price target upside is 100%
11 analysts

11

S

14

W

1

O

3

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Neogenomics Inc. Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '264006008001000Actual RevenueAvg. Estimate
Hit

Neogenomics Inc.'s Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

Current EPS
-0.6
Avg. Estimate
-0.6
Low Estimate
-0.7
High Estimate
-0.4
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 9.7% in FY25

Consensus Recommendation

14 ANALYST Recommendations
BUY

Created with Highcharts 7.2.24Hold3Buy7Strong Buy

The consensus recommendation from 14 analysts for Neogenomics Inc. is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Neogenomics Inc. Stock Analysis

Neogenomics Inc. stock analysis with key metrics, changes, and trends.

Neogenomics Inc. MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$660.57 M11.65%positive

Annual Revenue rose 11.65%, in the last year to $660.57 M. Its sector's average revenue growth for the last fiscal year was 8.01%.

Annual Net Profit$78.73 M10.51%positive

Annual Net Profit rose 10.51% in the last year to $78.73 M. Its sector's average net profit growth for the last fiscal year was 3.27%.

Price to Earning Ratio-15.47-negative

Price to Earning Ratio is -15.47, which is negative.

Stock Price$9.48-37.63%negative

Stock Price fell 37.63% and underperformed its sector by 40.9% in the past year.

Quarterly Revenue$172 M10.57%positive

Quarterly Revenue rose 10.57% YoY to $172 M. Its sector's average revenue growth YoY for the quarter was 9.55%.

Quarterly Net profit$15.32 M6.97%negative

Quarterly Net profit fell 6.97% YoY to $15.32 M. Its sector's average net profit growth YoY for the quarter was 35.04%.

Debt to Equity Ratio0.67-positive

Debt to Equity Ratio of 0.67 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-8.54 %-8.54%negative

Return on Equity(ROE) for the last financial year was -8.54%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding90.42 %-0.34%negative

Mutual Fund Holding decreased by 0.34% in the last quarter to 90.42.

Promoter Share Holding0.70 %-0.01%negative

Promoter Share Holding decreased by 0.01% in the most recent quarter to 0.7%.

Interest Coverage Ratio-11.19-negative

Interest Coverage Ratio is -11.19, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding96.90 %-1.61%negative

Institutional Holding decreased by 1.61% in the last quarter to 96.9.

VIEW LESS


Loading data..

Neogenomics Inc. - Company Profile

What does Neogenomics Inc. do?

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Neogenomics Inc. Management structure

All Gross Remunerations are in USD
Mr. Christopher M. Smith
Chief Executive Officer and Director
-
2025
Gross Remuneration
Year
Ms. Melody Harris
Chief Operations Officer and President, Informatics
-
2025
Gross Remuneration
Year
Mr. Warren Stone
Chief Commercial Officer
-
2025
Gross Remuneration
Year
Ms. Beth Eastland
Senior Vice President, Enterprise Sales
-
2025
Gross Remuneration
Year

Neogenomics Inc. Board of directors

All Gross Remunerations are in USD
Mr. Anthony P. Zook
Independent Director
-
2025
Gross Remuneration
Year
Mr. Christopher M. Smith
Chief Executive Officer and Director
-
2025
Gross Remuneration
Year

Neogenomics Inc. FAQ

How is Neogenomics Inc. today?
Neogenomics Inc. today is trading in the green, and is up by 0.74% at 9.48.
Neogenomics Inc. is currently trading up 0.74% on an intraday basis. In the past week the stock fell -4.53%. stock has been down -43.67% in the past quarter and fell -37.63% in the past year. You can view this in the overview section.